Figure 2.
Figure 2. CART analysis. CART analysis of F-refractory status and complex karyotype in patients who received ≥400 mg/d. Patients with unknown karyotype were excluded from analysis. TTP of any kind (both CLL and RT) according to (A) F-refractory status in patients with complex karyotype; (B) F-refractory status in patients with noncomplex karyotype; (C) karyotype complexity in patients with F-refractory disease; and (D) karyotype complexity in patients with non-F-refractory disease.

CART analysis. CART analysis of F-refractory status and complex karyotype in patients who received ≥400 mg/d. Patients with unknown karyotype were excluded from analysis. TTP of any kind (both CLL and RT) according to (A) F-refractory status in patients with complex karyotype; (B) F-refractory status in patients with noncomplex karyotype; (C) karyotype complexity in patients with F-refractory disease; and (D) karyotype complexity in patients with non-F-refractory disease.

Close Modal

or Create an Account

Close Modal
Close Modal